AstraZeneca has added to its oncology pipeline by licensing a small-molecule KRAS inhibitor from Chinese biotech Usynova for $24 million upfront. The compound – called UA022 – targets the KRASG12D ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results